Breaking Finance News

Shield Therapeutics Plc (LON:STX) target price held steady at 310.00GBX, reported today by Liberum Capital

Indicating a possible upside of 0.95%, Liberum Capital held the estimated target of Shield Therapeutics Plc (LON:STX) at 310GBX.

Previously on 8/11/2016, Canaccord Genuity reported on Shield Therapeutics Plc(LON:STX) raised the target price at 235.00GBX. At the time, this suggested an upside of 0.49%.

Displaying a price of 159.00GBX, Shield Therapeutics Plc (LON:STX) traded 1.92% higher on the day. The last close is down 4.22% relative to the 200-day moving average, compared with the S&P 500 which has decreased -0.01% over the same time period. The company has registered a 50-day moving average of 156.35GBX and 200-day average of 166.01GBX. Volume of trade was was up over the average, with 45,024 shares of STX changing hands over the typical 2,963 shares.

Recent Performance Graph:

Shield Therapeutics Plc (LON:STX)

With a total market value of 0.0 GBX, Shield Therapeutics Plc has a PE of 0 with a 52 week low of 147.00GBX and a 52 week high of 190.00GBX.

Brief Synopsis About Shield Therapeutics Plc (LON:STX)

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), and is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.